SEL-212

N/A

Report date: 2026/03/06 20:02:51

Base Information

Drug NameSEL-212
Drug Alias NamePegadricase-SVPPegsiticase-SVPNon-immunogenic uricaseSVP-Rapamycin/pegsiticaseSEL-212 +[9] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionUric acid stimulantsMethylmalonyl-CoA Mutase stimulantsSerine/threonine-protein kinase mTOR inhibitors
TargetsUric acidMethylmalonyl-CoA MutaseSerine/threonine-protein kinase mTOR
Therapy Area/IndicationsHyperuricemiaGout
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineSerbia +[5] 
CombinationsYes PegadricaseSEL 110
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesSelecta Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesSwedish Orphan Biovitrum AgSwedish Orphan Biovitrum (Sobi)Swedish Orphan Biovitrum Ab (Publ)
Inactive CompaniesSelecta Biosciences Inc
Active IndicationsGout
Inactive IndicationsHyperuricemia

Other Information

ATC CodeN/A
Related LinksN/A